Condition (MeSH)
Kidney Cortex Necrosis
ClinicalTrials.gov lists 10 trials for Kidney Cortex Necrosis or a narrower condition beneath it. SeaStar Medical has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Kidney Cortex Necrosis itself; the rest are tagged with a narrower condition beneath it.
When did Kidney Cortex Necrosis trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2008 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Kidney Cortex Necrosis trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 2/3 | 3 |
| Phase 3 | 1 |
| Not applicable | 3 |
| Observational | 2 |
How many Kidney Cortex Necrosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 2 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Kidney Cortex Necrosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| SeaStar Medical | 3 |
| Ebima Clifford Okundaye | 1 |
| RenaMed Biologics | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Nicotinamide treatment | 1 |
| MAP-Target Algorithm | 1 |
| QRX-3 | 1 |
| Fenoldopam Mesylate and/or MESNA | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Kidney Cortex Necrosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac disorders | 22 | 1 |
| Infections and infestations | 22 | 1 |
| Respiratory, thoracic and mediastinal disorders | 20 | 1 |
| Blood and lymphatic system disorders | 11 | 1 |
| General disorders and administration site conditions | 11 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Kidney Cortex Necrosis? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2015 | No |
| The urine sediment as a biomarker of kidney disease. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2015 | No |
| Cardiopulmonary bypass-associated acute kidney injury: a pigment nephropathy? | Contributions to nephrology | 2007 | No |
| Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. | The Journal of clinical investigation | 2005 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.